Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Tuesday, November 24, 2009, 3:13pm EST - Canadian Markets close in 47 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
VIVUS Inc. (VVUS)
At 14:58 EST:
8.37 USD
0.17 (1.99%)
MORE ON VVUS
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
VIVUS, Inc.
(NGM:VVUS) Delayed quote data
Last Trade:
8.37 USD
Trade Time:
2:58PM EST
Change:
0.17 (1.99%)
Prev Close:
8.54
Open:
8.43
Bid:
8.37
x 2300
Ask:
8.38
x 2500
1y Target Est:
7.80
Day's Range:
8.20 - 8.50
52wk Range:
2.72 - 12.88
Volume:
1,442,243
Avg Vol
(3m)
:
6,132,120
Market Cap:
674.20M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.24
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add VVUS to Portfolio
Download Data
HEADLINES
3 Stocks Ready to Roar
at Motley Fool
(Tue 2:00pm)
The Side Effect of Developing Obesity Drugs
at Motley Fool
(Mon 4:13pm)
Poniard Finds Cash to Keep Lights On: BioBuzz
at TheStreet.com
(Mon 12:59pm)
Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz
at TheStreet.com
(Mon 10:14am)
FDA Issues New Obesity Drug Heart Warning: BioBuzz
at TheStreet.com
(Mon 8:15am)
Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript
(Fri, Nov 20)
Biotech Stock Mailbag: FDA Playbook
at TheStreet.com
(Fri, Nov 20)
CTT's Pain Mangement Device Sales to Result in Positive Surprise in 10Q
at Seeking Alpha
(Thu, Nov 19)
Trading Biotech Breakthroughs
at CNBC
(Wed, Nov 18)
Coventry, BJ's Wholesale, Vivus are big movers
AP
(Wed, Nov 18)
UPDATE - Vivus says erectile dysfunction trial meets goals
at Reuters
(Wed, Nov 18)
More Headlines for VVUS...
ANALYST
EPS Est (next year)
(Dec-07)
:
N/A
EPS Est (in 2 years)
(Dec-08)
:
N/A
Avg Rec (current)*:
2.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
VIVUS, Inc., a pharmaceutical company, engages in the development and commercialization of therapeutic products to treat obesity, post-menopausal, and sexual health in women and men in the United States.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices